Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$0.86
-$0.07(-5.60%)
At close: 4:00 PM EST
$0.86
-$0.07(-5.60%)
Day’s Range― - ―
52-Week Range$4.25 - $31.50
Previous CloseN/A
Volume59.48K
Average Volume (3M)182.02K
Market Cap
$78.10M
Enterprise Value$28.67
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.71
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding16,832,014
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Acceleration (RMAT)RMAT designation creates an expedited, engagement-focused regulatory pathway and a Type B meeting with FDA. This materially improves development clarity and could shorten timelines to pivotal endpoints, lowering regulatory execution risk over the next 2–6 months.
Progressing Phase 2b ProgramActive enrollment and first U.S. dosing in a randomized, powered Phase 2b across US, Denmark and Poland demonstrates clinical execution capability and expands regulatory footprints. Ongoing trial activity supports the company’s ability to generate durable, potentially pivotal clinical data.
Large Digital-asset TreasuryA sizable RAIN token holding provides a substantial non-dilutive liquidity buffer and alternative funding optionality for R&D or partnerships. As a structural treasury strategy, it diversifies capital sources and can materially support operations if token liquidity and markets remain accessible.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flows indicate the business cannot self-fund development and remains dependent on external financing or asset monetization. This structural funding gap raises dilution and execution risk until operating cash generation improves.
No Product Revenue / Operating LossesAbsence of recurring product revenue and persistent negative margins mean enterprise value is driven entirely by clinical success prospects. Without operating leverage, long-term sustainability depends on successful trials, approvals, or partnerships rather than existing commercial cash flow.
Nasdaq Listing Compliance RiskA formal minimum bid-price deficiency creates a multi-month compliance overhang that can restrict access to certain investors and capital markets. Remedies (reverse splits, extensions) may dilute shareholders or signal fragility, affecting strategic financing options until resolved.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $4.25 and its highest was $31.50 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $78.10M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 274 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Overvalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 16,832,014 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -0.38%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Technical Analysis
Ownership Overview
―
Insiders
0.18% Mutual Funds
― Other Institutional Investors
99.41% Public Companies and
Individual Investors